WO2003018019A3 - New use of cyclic compounds - Google Patents

New use of cyclic compounds Download PDF

Info

Publication number
WO2003018019A3
WO2003018019A3 PCT/JP2002/008443 JP0208443W WO03018019A3 WO 2003018019 A3 WO2003018019 A3 WO 2003018019A3 JP 0208443 W JP0208443 W JP 0208443W WO 03018019 A3 WO03018019 A3 WO 03018019A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
salt
hydrogen
compound
formula
Prior art date
Application number
PCT/JP2002/008443
Other languages
French (fr)
Other versions
WO2003018019A2 (en
Inventor
Takuma Oku
Yoshitaka Hirayama
Kaoru Yamagami
Yoshitaka Ohkubo
Hideaki Matsuoka
Original Assignee
Fujisawa Pharmaceutical Co
Takuma Oku
Yoshitaka Hirayama
Kaoru Yamagami
Yoshitaka Ohkubo
Hideaki Matsuoka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Takuma Oku, Yoshitaka Hirayama, Kaoru Yamagami, Yoshitaka Ohkubo, Hideaki Matsuoka filed Critical Fujisawa Pharmaceutical Co
Priority to AU2002313591A priority Critical patent/AU2002313591A1/en
Publication of WO2003018019A2 publication Critical patent/WO2003018019A2/en
Publication of WO2003018019A3 publication Critical patent/WO2003018019A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An agent comprising a compound of Formula (I-a) and the like, or a salt thereof, use of a compound of Formula (I-a) and the like, or a salt thereof for the manufacture of a medicament, or a method comprising administering a compound of Formula (I-a) and the like, or a salt thereof, for the treatment of Inflammatory respiratory disease in which: Aa is a sulfonyl or a carbonyl; R1a is an optionally substituted aryl, etc; R2a is a hydrogen, etc; R3a is an optionally substituted lower alkyl, etc; R4a is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5a is a hydrogen, etc; and R6a is a hydroxy or a protected hydroxy.
PCT/JP2002/008443 2001-08-24 2002-08-21 New use of cyclic compounds WO2003018019A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002313591A AU2002313591A1 (en) 2001-08-24 2002-08-21 New use of cyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR7262 2001-08-24
AUPR7262A AUPR726201A0 (en) 2001-08-24 2001-08-24 New use of a cyclic compound

Publications (2)

Publication Number Publication Date
WO2003018019A2 WO2003018019A2 (en) 2003-03-06
WO2003018019A3 true WO2003018019A3 (en) 2003-12-04

Family

ID=3831215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008443 WO2003018019A2 (en) 2001-08-24 2002-08-21 New use of cyclic compounds

Country Status (2)

Country Link
AU (1) AUPR726201A0 (en)
WO (1) WO2003018019A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926707B (en) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 A kind of synthetic method of pharmaceutical intermediate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020824A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
WO1998008825A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company 1,4-heterocyclic metalloprotease inhibitors
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
WO1998034918A1 (en) * 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
WO2000044709A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
EP1081137A1 (en) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
WO2002067866A2 (en) * 2001-02-27 2002-09-06 Axys Pharmaceuticals, Inc. Piperazine derivatives as metalloprotease inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020824A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
WO1998008825A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company 1,4-heterocyclic metalloprotease inhibitors
WO1998027069A1 (en) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Piperazine compounds as inhibitors of mmp or tnf
WO1998034918A1 (en) * 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
WO2000044709A2 (en) * 1999-01-27 2000-08-03 American Cyanamid Company ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
EP1081137A1 (en) * 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
WO2002067866A2 (en) * 2001-02-27 2002-09-06 Axys Pharmaceuticals, Inc. Piperazine derivatives as metalloprotease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG M ET AL: "DESIGN AND SYNTHESIS OF PIPERAZINE-BASED MATRIX METALLOPROTEINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 3, 2000, pages 369 - 380, XP000919159, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
AUPR726201A0 (en) 2001-09-20
WO2003018019A2 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
WO2008133273A1 (en) Pharmaceutical composition for treatment of alzheimer's disease
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
IN2015DN01132A (en)
UA88477C2 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
AU2003244450A1 (en) Formulations for inhalation
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2006034446A3 (en) Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
EP1505068A4 (en) PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
NZ545506A (en) Therapeutic agents useful for treating pain
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
WO2006067392A3 (en) Indole derivatives for the treatment of tuberculosis
EP1839662A4 (en) Antitumor agent
WO2000068198A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
TWI349674B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof
CA2402991A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
WO2006078724A3 (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
EP1669345A4 (en) Ester derivative and medicinal use thereof
WO2003018019A3 (en) New use of cyclic compounds
WO2008136377A1 (en) Bicyclic heterocyclic compound
MX2007003911A (en) Benzoxazine and quinoxaline derivatives and uses.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
NZ542305A (en) Treatment of proliferative diseases with an epothilone derivative and radiation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP